Abstract
leading cause of chronic kidney disease and in the following years that same thing is expected to happen in developing countries as a result of overall increase of type 2 diabetes mellitus (T2DM) and obesity [4] . In our country, diabetes occupies first place (14.8%) among the diseases that lead to end stage renal disease [5] .
Several studies indicated that glycemic variability seems to be an independent cardiovascular risk factor and has more deleterious effects on endothelial function compared to sustained hyperglycemia, especially due to oxidative stress activation [6] [7] [8] [9] .
Glycated hemoglobin (HbA1c) is considered the gold standard for the assessment of glycemic control. In CKD patients there are many factors which could lead to false and misleading values of HbA1c [9] . Among the factors that lead to falsely low HbA1c values are: reduce erythrocytes lifespan, hemolysis, iron deficiency, repeated transfusions, erythropoiesis stimulating agents [10] . Falsely high HbA1c levels are induced by hemoglobin carbamylation [11, 12] . Also HbA1c is not able to identify glycemic variability. Therefore it is necessary to identify methods to assess glycemic excursions in CKD patients [13] .
Continuous glucose monitoring system may represent an useful tool that allows glycemic variability quantification and also efficient discrimination between the sustained chronic hyperglycemia and acute glucose fluctuation [8, 14] .
We hypothesize that the assessment of glycemic variability using CGMS recordings may provide a more accurate evaluation of the metabolic status in patients with CKD. In order to test this hypothesis, we assessed the glycemic variability indices estimated on 72 hours CGMS readings in 30 subjects stratified according to the presence of CKD and diabetes. We also attempted to identify the predictive value of inter-day and intra-day glycemic variability indices for the poor glycemic control (HbA1c≥6,5%) in analyzed subjects.
Material and method

Subjects
In this cross -sectional study we included 20 diabetic patients (10 patients with CKD and 10 patients without CKD) and 10 healthy volunteers. Normal kidney function was defined as estimated glomerular filtration rate (eGFR) > 90 mL/min per 1.73 m 2 and no albuminuria (urine albumin-creatinine ratio <30 mg/g). CKD stage 2-4 was defined as eGFR = 90-15 mL/min per 1.73 m 2 . The patients were recruited consecutively from the patients routinely visiting the Nephrology Ambulatory for CKD patients and, respectively, the Diabetes Ambulatory for diabetic patients. The inclusion criteria were: signing of inform consent for participation in the study, CKD stage 2-4 for the CKD group and diagnosis of T2DM for the diabetes group.
Exclusion criteria were all conditions that can increase glycemic variability: acute diseases (infections, surgery, myocardial infarction, stroke, etc.,); chronic consumptive diseases (chronic hepatitis, tuberculosis, human immunodeficiency virus infection, malignancies, etc) that decrease appetite thus modifying carbohydrates intake; pregnancy and lactation (hormonal profile influence glucose metabolism) and mental illnesses (difficulty in CGMS monitoring). The study was performed according to the Helsinki declaration and the good clinical practice guidelines and the study was approved by the Ethics Committee of University of Medicine and Pharmacy Craiova.
Study protocol
The CGMS sensor (DexCom SEVENPLUS) was subcutaneously inserted for 72 hours, allowing interstitial glucose measurement every 5 minutes. The CGMS calibration was performed by recording at least 4 selfmonitoring capillary blood glucose with a glucose meter. All the subjects had the same carbohydrates intake according to nutritionist's recommendation.
The following data were recorded: demographic characteristics, medical history (type 2 DM duration, current therapy), anthropometric parameters. HbA1c was measured in all subjects.
The next glycemic variability indices were assessed on CGM readings using the GlyCulator application [ 
Statistical analysis
Continuous variables are expressed as means ± standard deviation; categorical variables are expressed as percentages. The variables were tested for normal distribution using the Kolmogorov-Smirnov test. Comparisons between different groups were performed using parametric or nonparametric tests, depending of the variables distribution.
Receiver operating characteristic (ROC) curves were used to determine the predictive utility of glycemic parameters in identifying poor glycemic control quantified by HbA1c≥6.5%. Multiple stepwise regression was assessed in order to establish the independent predictors for glycemic imbalance. Values of p < 0.05 were considered significant. SPSS19.0 software was used for analysis.
Results
The subjects included in the present study were stratified in 3 groups, according to the presence of CKD and diabetes: CKD diabetic patients (T2DM+/CKD+), diabetic patients without CKD (T2DM+/CKD-) and healthy volunteers subjects (T2DM-/CKD-). Glycemic variability indices distribution in the study groups is presented in Table 1 .
The CKD diabetic patients presented interday variability (quantified by MODD) and intraday glycemic variability (quantified by MAGE, % CV, CONGA at 1, 2, 4 and 6 h) significantly higher compared to the diabetic patients without CKD. Likewise MIG was higher in the CKD diabetic patients, compared to the diabetic patients without CKD (Table 1, Figure 1, 2, 3) . The diabetic patients with CKD had important inter-day and intra-day glycemic variability and also, statistically significant higher percentage of time with interstitial glucose above 180 mg/dl and FD, compared to the healthy subjects (Table 1, Figure 1, 2, 3 ).
HbA1c levels were significantly higher in the diabetic subjects compared to healthy subjects, regardless to the presence of CKD (Table 1, Figure 3 ). However there were no significant differences in HbA1c between diabetic subjects with or without CKD. ROC curves indicated that MIG, MAGE, MODD and the percentage of time with blood glucose above 180 mg/dl had higher predictive value for metabolic imbalance assessed by HbA1c≥6.5% (Table 2, Figure 4 ).
Multiple stepwise linear regression showed that only the percentage of time with blood glucose above 180 mg/dl (p=0.024) was an independent predictor for HbA1c≥6.5% (Table 3 ). 
Discussions
The outcomes observed in the actual study indicated that diabetic patients with CKD had statistic significantly higher inter-day (MODD) and intra-day (MAGE, %CV, CONGA 1h, 2h, 4h, 6h, MIG) glycemic variability comparative to diabetic and non-diabetic subjects with normal kidney function. The HbA1c was higher in CKD diabetic patients than in diabetic patients without CKD but the differences did not reach statistical significance. This data suggest that HbA1c is not a reliable marker of poor glycemic control in subjects with CKD, due to the multitude of factors that induce glycemic variability. Our findings are in accordance with other studies that show the lack of correlation between mean interstitial glucose assessed on CGMS recordings and HbA1c, indicating that CGMS could be more accurate in the evaluation of realtime glycemic control in this patients category [21] [22] [23] .
Diabetic patients with CKD presented mean interstitial glucose and also interstitial glucose values above 180mg/dl and below 70mg/dl on longer time period comparative with diabetic subjects and non-diabetic subjects with normal kidney function. Only the differences between CKD diabetic patients and healthy volunteers regarding the percent of time with glucose above 180mg/dl were statistically significant. Fractal dimension was significantly higher in CKD diabetic subjects comparative to healthy volunteers, indicating that CKD is associated with high frequency low amplitude glycemic excursions. This data indicated that the presence of CKD induces important glycemic excursions. This could be justified by the presence of CKDinduced insulin resistance leading to hyperglycemia which coexists with risk of hypoglycemia due to malnutrition, an increased half-life of insulin and a reduced rate of gluconeogenesis [24] .
To date there have been no studies examining the correlation between glycemic variability indices quantified on CGM readings and markers of glycaemic control to determine which biomarker most accurately characterizes the glycaemic control in diabetic patients with predialysis stages of CKD.
Analyzing the area under the ROC curves we observed that MAGE, MODD, MIG and % time with glucose above180mg/dl had predictive value for poor glycemic control (HbA1c ≥6.5%) but only the period of time spent with glucose above 180 mg/dl had an independent predictive value according to multiple stepwise regression.
This proof-of-principle study has limitations due to the sample size, the results from this sample data are strongly suggestive that a larger study on the glycemic variability in subjects with CKD should be encouraged and that the identification of glycemic variability indices using CGMS may be relevant to metabolic control of CKD patients. The lack of matching demographic and anthropometric characteristics of the study groups and the control group represents another limitation of this study.
Conclusions
In summary the current study provides evidence that subjects with CKD and T2DM had important metabolic imbalance and significant glycemic variability compared to diabetic patients without CKD. and especially to healthy subjects.
Since only the percentage of time with recorded blood glucose > 180 mg/dl was an independent predictor for HbA1c. our findings emphasize that HbA1c is not enough for metabolic imbalance assesment. the use of other glycemic variability indices being also useful.
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